Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last SFr.1.84 CHF
Change Today 0.00 / 0.00%
Volume 0.0
As of 3:54 PM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

evolva holding sa (EVE) Snapshot

Open
SFr.1.75
Previous Close
SFr.1.75
Day High
SFr.1.85
Day Low
SFr.1.75
52 Week High
05/27/15 - SFr.1.85
52 Week Low
08/6/14 - SFr.1.07
Market Cap
602.7M
Average Volume 10 Days
2.9M
EPS TTM
SFr.-0.08
Shares Outstanding
327.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EVOLVA HOLDING SA (EVE)

Related News

No related news articles were found.

evolva holding sa (EVE) Related Businessweek News

No Related Businessweek News Found

evolva holding sa (EVE) Details

Evolva Holding SA, a biosynthetic company, discovers, develops, manufactures, and commercializes ingredients for nutrition, health care, and wellness products in Switzerland and internationally. The company’s principal products include Resveratrol, a natural compound produced in grapes and other plants as a response against environmental stress factors; Vanillin, a complex blend of compounds extracted from the seed pods of the vanilla orchid; and Stevia, a natural, zero-calorie food, and beverage sweetener derived from Stevia rebaudiana, a leafy green plant for family. It also offers Nootkatone, a citrus ingredient associated with grapefruits, which is used as a flavor and fragrance ingredient; and as agent against a range of insect pests, including ticks, bed bugs, and mosquitoes. In addition, the company provides Agarwood for perfume makers and traditional medicine practitioners; Saffron, a spice made by yeast fermentation; Valencene, an orange flavor and fragrance ingredient used in food and drink, personal care, and household products, as well as an intermediate to produce nootkatone; and Sandalwood, an oil used in preparing various types of perfume compositions. Further, it offers legacy products, such as EV-077, a compound for diabetic nephropathy and other diabetic complications; EV-35, a preclinical antibiotic; and Pomecins, an antifungal ingredient that prevent mould and yeast growth. The company is based in Reinach, Switzerland.

144 Employees
Last Reported Date: 03/31/15

evolva holding sa (EVE) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: SFr.388.7K
Compensation as of Fiscal Year 2014.

evolva holding sa (EVE) Key Developments

Cargill and Evolva Agree to Begin Engineering Work on Production Facility for Next-Gen Stevia Sweeteners

Evolva and Cargill have agreed to begin the engineering phase for converting an existing Cargill manufacturing facility to produce next-generation stevia sweeteners (steviol glycosides). The ingredients are expected to be commercially available in 2016. Stevia-based sweeteners are highly sought-after natural, zero-calorie sweeteners. However, their broader use is currently constrained by their taste at high usage levels, which can be bitter or have an after-taste. Certain stevia sweetener molecules such as Reb D and Reb M do not have this problem, but, because they only make up a tiny portion of the plant's leaf (much less than 1%), it is prohibitively costly to obtain them from the stevia plant. Fermentation removes these constraints and should allow a dramatic expansion in the use of next generation stevia sweeteners, allowing food and beverage producers to create new classes of lower calorie products that taste great and are affordable to all. These sweeteners will be produced in a Cargill fermentation system in Blair, Nebraska. Using a larger existing facility gives the companies the flexibility to expand rapidly and cost-effectively to meet commercial demand.

Evolva Holding SA. Announces Consolidated Earnings Results for the Full Year Ended December 31, 2014; provides earnings guidance for the year 2015

Evolva Holding SA. announced consolidated earnings results for the full year ended December 31, 2014. For the year, the company reported revenues of CHF 10.7 million against CHF 8.7 million a year ago. Net loss was CHF 21.8 million or CHF 0.08 per share against CHF 16.2 million or CHF 0.07 per share a year ago. The operating cash outflow increased to CHF 19.8 million compared to CHF 12.5 million a year ago due to the higher net operating loss. Investments (capex) amounted to CHF 1.2 million, primarily related to purchase of new lab equipment needed to move forward key projects. The company expects revenues to increase by at least 30% in 2015. Product sales will make a meaningful contribution for the first time, however a significant majority of revenues will still derive from R&D partnerships. The company is currently in discussions with Cargill regarding the potential exercise of 45% option on stevia. If exercised, the company expects this to lead to a significant cash outflow in 2015 as they invest alongside Cargill to bring stevia to market in 2016.

Evolva and Valent BioSciences to Co-Develop Agricultural Bioactives

Evolva and Valent BioSciences Corporation (VBC), a subsidiary of Sumitomo Chemical Company, have signed an exclusive agreement to co-develop and commercialise a class of high-value active ingredients for use as next-generation agricultural bioactives. For competitive reasons, the ingredients are not being identified at this time. Bioactives are being used increasingly around the globe because they help growers improve crop yields without any negative effects to either human health or the environment. They are used in both organic and conventional agriculture and horticulture. Along with crop rotation and integrated pest management strategies, bioactives play an important role in sustainable farming. The collaboration will start by developing yeast strains that make the desired ingredients. Evolva has the primary responsibility for this phase while VBC will be responsible for commercialisation. The companies will work together on scale-up and manufacturing. The first products from the collaboration are expected to be launched in 4-5 years. Total spending on the project during the next five years is estimated at CHF 12-14 million. Evolva and VBC have agreed to split equally both the R&D costs and profits from active ingredient sales.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EVE:SW SFr.1.84 CHF 0.00

EVE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EVE.
View Industry Companies
 

Industry Analysis

EVE

Industry Average

Valuation EVE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 49.5x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 49.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EVOLVA HOLDING SA, please visit www.evolva.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.